Amarin Corp. (AMRN) Misses Q3 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Micron rises as White House presses Apple to avoid Chinese memory chips
Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations
February 27, 2019 5:00 AM ESTRecord Revenue of $229.2 Million and $77.3 Million for Full Year and Fourth Quarter 2018 Â
REDUCE-IT sNDA Submission Remains on Schedule to be Filed Before the End of Q1 2019
Management to Host Conference Call at 7:30 a.m. ET Today
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced financial results for the quarter and year ended December 31, 2018 and provided an update on company operations.
Key Amarin... More
